Skip to main content

Effective bleed control for people with acquired hemophilia.

NovoSeven® RT is the only bypassing agent that is approved by the FDA for acquired hemophilia.

Effective bleed control for people with acquired hemophilia.

NovoSeven® RT is the only bypassing agent that is approved by the FDA for acquired hemophilia.

Proven to be effective.

As a first-line treatment, NovoSeven® RT is 92% effective and recommended by an international consensus.

Acquired Hemophilia: NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) was 92% effective as first-line treatment

Lower volume means fast infusion.

Because it's a low-volume treatment, NovoSeven® RT takes 2 to 5 minutes to infuse.a  


a
Administer as a slow bolus injection over 2 to 5 minutes, depending on the dose administered.

bBased on the initial dose for a 70-kg patient with acute bleeding.


Established safety profile.

Recombinant manufacturing means NovoSeven® RT is made without any human blood or plasma, which minimizes the possibility of viral contamination. And in a clinical trial, 4% of patients with acquired hemophilia experienced adverse events (blood clots).

Icon: Microscrope

What if I need surgery or a procedure?

We understand that you have concerns about controlling bleeds if you ever need surgery or a procedure. The good news is that NovoSeven® RT is effective for preventing bleeds during and after surgery and procedures in people with acquired hemophilia.

Talk to your doctor for more information on the surgical use of NovoSeven® RT.

What about surgery and procedures?

Approved for surgical use and procedures for patients with acquired hemophilia.

Young man and boy standing

Hear from people who

share your experience.


Illustration: Removing syringe cap

New to treatment? It's

easy to get started.


Icon: 5-step purification process of NovoSeven® RT (Coagulation Factor VIIa [Recombinant])

Recombinant manufacturing

minimizes risk of viral contamination.


Selected Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

What is NovoSeven® RT?

NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
  • You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

What should I tell my healthcare provider before using NovoSeven® RT?

  • Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
    • congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
    • are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
    • history of heart or blood vessel diseases
  • Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

What are the possible side effects of NovoSeven® RT?

  • The most common and serious side effects are blood clots
  • Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please click here for Prescribing Information